ZP-Triptan

**ZP-Triptan** is a patented microneedle patch formulation of **zolmitriptan**, a selective serotonin (5-HT1B/1D) receptor agonist, designed for rapid transdermal delivery during acute migraine attacks. Applied to the upper arm, it provides fast absorption kinetics demonstrated in Phase 1 trials, aiming for quick pain relief without injection or gastrointestinal issues associated with oral triptans. Developed by **Zosano Pharma**, it was evaluated in a multicenter, randomized, placebo-controlled pivotal efficacy trial (Zotrip) comparing doses of 1.0 mg, 1.9 mg, and 3.8 mg against placebo, with co-primary endpoints of pain freedom and most bothersome symptom relief at 2 hours post-dose. The program advanced to late-stage development around 2016-2017, focusing on superior onset compared to traditional zolmitriptan.[1][4][7][8]

Brand names

Qtrypta

Other names

M207M-207M 207